Eli Lilly and Company (LLY · NYSE)
LLY · MARKET VIEW
Market view · as of Oct 12, 2026
Price (last ~year)
Eli Lilly (LLY, $1.05T market cap) delivered 47.7% year-over-year revenue growth with TTM revenue of $79.67B, and has beaten consensus estimates in all four of its most recent quarters, including a June quarter EPS of $8.38 versus $6.01 expected. Quarterly revenue climbed from $17.60B in September 2025 to $22.97B in June 2026, with operating income rising to $12.46B over the same span. Margins are exceptional—83.4% gross, 54.2% operating, 33.5% net—with ROE of 102.3%, while leverage remains modest at 1.3x debt/EBITDA and June-quarter free cash flow totaled $7.76B. The stock closed at $1,179.27, up 5.7% over the past month and 9.8% above its 200-day SMA, though it trades at a premium 39.59 P/E and sits 7.9% below its 52-week high.
Valuation
- Market cap
- $1.05T
- P/E
- 39.59
- PEG
- 1.137
- P/B
- 30.28
- P/S
- 13.2
- EV/EBITDA
- 25.7
- Beta
- 0.453
- Analyst target
- $1330.14
Quality & returns
- Gross margin
- 83.4%
- Operating margin
- 54.2%
- Profit margin
- 33.5%
- ROE
- 102.3%
- ROA
- 20.4%
Price movement
- Last
- $1179.27
- 1-month
- +5.7%
- 3-month
- +1.0%
- RSI (14)
- 54
- vs SMA200
- +9.8%
- 52-wk position
- 79.2% -7.9% vs high
Quarterly trajectory
Revenue by quarter (oldest → newest)
| Quarter | Revenue | Op income | Net income | EBITDA |
|---|---|---|---|---|
| 2026-06-30 | $22.97B | $12.46B | $7.09B | $12.99B |
| 2026-03-31 | $19.80B | $9.78B | $7.40B | $10.29B |
| 2025-12-31 | $19.29B | $8.99B | $6.64B | $12.14B |
| 2025-09-30 | $17.60B | $8.39B | $5.58B | $7.88B |
Recent news
- Somewhat-Bullish Which Healthcare ETF Is the Better Buy: Fidelity’s Broad FHLC or Invesco’s Biotech-Focused PBE? · 2026-10-11
- Somewhat-Bullish Novo Nordisk CEO Stresses 'Quality of Weight Loss' in Obesity Drugs · 2026-10-11
- Somewhat-Bullish CVS Health (NYSE:CVS) Stock Bumped Up to Strong-Buy by Wall Street Zen · 2026-10-11
- Neutral Form 144 ELI LILLY AND COMPANY For: 11 October By Investing.com · 2026-10-11
- Somewhat-Bullish Better Pharma ETF: iShares IHE vs. State Street XPH · 2026-10-10
- Somewhat-Bullish Analysts Offer Insights on Healthcare Companies: Eli Lilly & Co (LLY), Legend Biotech (LEGN) and Bristol-Myers Squibb (BMY) · 2026-10-10
Sources this view read
- fundamentals Company overview & valuation (Alpha Vantage OVERVIEW)
- filing Quarterly financial statements (Alpha Vantage INCOME/BALANCE/CASH)
- earnings Reported earnings history (Alpha Vantage EARNINGS)
- prices Adjusted daily prices (Alpha Vantage TIME_SERIES_DAILY_ADJUSTED)